ATLATL brings together a full suite of 11 integrated R&D platforms designed to help teams move from idea to proof-of-concept to development faster. Covering key areas from discovery to translational research, our platforms include Exosome, Pathology, Imaging, Animal Study, FACS & Cell Sorting, Cell Manufacturing, Drug Screening, Cell & Gene Therapy, Organoid, Single-Cell Research, and Multi-Omics.

Each platform is built around a common model: on-site execution, shared infrastructure, and expert collaboration. Scientists work side-by-side with specialized teams, CRO partners, and instrument experts in a single environment, enabling real-time iteration, rapid troubleshooting, and high-quality data generation.

Together, these platforms form a connected system that spans biological understanding, functional validation, and therapeutic development. From identifying targets and screening compounds to validating mechanisms and advancing new therapies, ATLATL provides an end-to-end R&D environment that reduces time, cost, and risk—while accelerating decision-making.

By integrating physical infrastructure, technical capabilities, and execution under one roof, ATLATL empowers innovators to focus on science and move forward with confidence.